TACE treatment

PROCEDURE2 trials

Sponsors

Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University

Conditions

CTLA-4Hepatocellular CarcinomaHepatocellular Carcinoma (HCC)ImmunotherapyPD-1PreoperativeTACE

Phase 2

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Not yet recruitingNCT07128251

Anhui Provincial HospitalHepatocellular Carcinoma (HCC), Immunotherapy, PD-1 +2

Start: 2025-08-20End: 2029-12-30Target: 47Updated: 2025-08-17

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Not yet recruitingNCT07131501

The First Affiliated Hospital with Nanjing Medical UniversityHepatocellular Carcinoma, Immunotherapy, Preoperative +2

Start: 2025-08-11End: 2029-08-31Target: 48Updated: 2025-08-20